actinium pharmaceuticals inc (ATNM) Key Developments
Actinium Pharmaceuticals, Inc Appoints Richard E. Champlin to Scientific Advisory Board
Sep 10 14
Actinium Pharmaceuticals, Inc. announced the addition of Richard E. Champlin, M.D. of MD Anderson Cancer Center to its Scientific Advisory Board (SAB) for Iomab(TM)-B, the company's radioimmunotherapy asset which is preparing to enter a Phase III pivotal trial. Dr. Champlin is in his twenty-fifth year at MD Anderson Cancer Center in Houston, Texas. He holds the titles of Chair, Department of Stem Cell Transplantation and Cellular Therapy; Professor of Medicine; and Associate Division Head, Division of Cancer Medicine.
Actinium Pharmaceuticals, Inc. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014
Sep 10 14
Actinium Pharmaceuticals, Inc. Presents at 14th Annual Biotech in Europe Forum for Global Partnering & Investment, Sep-30-2014 through Oct-01-2014. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH-4005 Basel, Switzerland. Presentation Date & Speakers: Sep-30-2014, Dragan Cicic, Chief Operating Officer and Chief Medical Officer, Sandesh C. Seth, Chairman and Member of Compensation Committee.
Actinium Pharmaceuticals, Inc. Files Orphan Drug Application for Use of Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
Sep 3 14
Actinium Pharmaceuticals, Inc. announced that it has filed an application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for Actimab-A, a radiolabeled antibody being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase 1/2 clinical trial. The company expects to provide interim results for the Actimab-A trial around the same time as the American Society of Hematology (ASH) meeting in December 2014. Patients over age 60 comprise the majority of those diagnosed with acute myeloid leukemia (AML), but treatment approaches in this population are limited because a majority of these individuals are judged too frail and unable to tolerate standard induction chemotherapy. Orphan drug designation is granted to treatments that are expected to provide significant therapeutic advantage over existing treatments and that target conditions affecting 200,000 or fewer U.S. patients per year. Orphan-designated drugs are eligible for incentives such as a faster approval process and additional market exclusivity. Actimab-A is a radiolabeled antibody being developed for newly diagnosed AML in patients over 60, and is currently in a multicenter Phase I/II clinical trial. Based on Actinium's alpha-particle immunotherapy (APIT) platform, Actimab-A consists of the CD33 antibody lintuzumab linked to the actinium-225 payload. Actimab-A has attracted support from experts at the high-volume cancer treatment hospitals due to the potential of its safety and efficacy profile, as well as its potential potency, specificity and ease of use. Clinical trials are being conducted at cancer institutions such as Memorial Sloan Kettering Cancer Center, Johns Hopkins Medicine, University of Pennsylvania Health System, Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center and the Texas Oncology-Baylor Charles A. Sammons Cancer Center. The Company expects interim Phase I/II clinical trial results in December 2014. Actimab candidates are in early development for other cancers.
Actinium Pharmaceuticals, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 10:00 AM
Sep 3 14
Actinium Pharmaceuticals, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 10:00 AM. Venue: Millennium Broadway Hotel & Conference Center, 145 West 44th Street, New York, New York, United States. Speakers: Kaushik J. Dave, Chief Executive Officer, President, Interim Chief Financial Officer, Principal Accounting Officer and Director.
Actinium Pharmaceuticals, Inc. Announces Launch of Additional Antibody Actinium-225 Labeling Program
Jul 16 14
Actinium Pharmaceuticals, Inc. initiated development of an additional antibody construct labeled with actinium-225. The antibody has potential to be used in treatment of a number of blood cancers. Preclinical work for this additional antibody will be done at Memorial Sloan Kettering Cancer Center. A significant amount of both clinical and preclinical data for the antibody labeled with other payloads is available from numerous clinical trials in a number of indications. Arming a versatile antibody with actinium-225 will allow further customization of treatment in various blood cancer indications and its use in expanded clinical settings due to very low levels of radiation exposure to medical personnel, other caregivers and environment. Pending successful results of the preclinical work, development will continue in clinical trials. Alpha emitters deposit higher energy over a much shorter distance compared with beta emitters, providing single-cell kill while sparing normal surrounding tissue. Increased cell-specific potency may provide less off-target toxicity, resulting in an approach that decreases relapse rates and is better tolerated by patients. Alpha emitters may prove particularly useful for minimal-residual disease or extramedullary disease (located outside of the bone marrow), as well as in the non- hematopoietic stem cell transplantation (HSCT) setting, if conjugated/connected to select target antigens. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first demonstrated at Memorial Sloan Kettering Cancer Center.